TY - JOUR
T1 - SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma
AU - Lospinoso, Severini L.
AU - Loricchio, E.
AU - Navacci, S.
AU - Basili, I.
AU - Alfonsi, R.
AU - Bernardi, F.
AU - Moretti, M.
AU - Conenna, M.
AU - Cucinotta, A.
AU - Coni, S.
AU - Petroni, M.
AU - De, Smaele E.
AU - Giannini, G.
AU - Maroder, M.
AU - Canettieri, G.
AU - Mastronuzzi, Angela
AU - Guardavaccaro, D.
AU - Ayrault, O.
AU - Infante, P.
AU - Bufalieri, F.
AU - Di, Marcotullio L.
PY - 2024
Y1 - 2024
N2 - The Sonic Hedgehog (SHH) pathway is crucial regulator of embryonic development and stemness. Its alteration leads to medulloblastoma (MB), the most common malignant pediatric brain tumor. The SHH-MB subgroup is the best genetically characterized, however the molecular mechanisms responsible for its pathogenesis are not fully understood and therapeutic benefits are still limited. Here, we show that the pro-oncogenic stemness regulator Spalt-like transcriptional factor 4 (SALL4) is re-expressed in mouse SHH-MB models, and its high levels correlate with worse overall survival in SHH-MB patients. Proteomic analysis revealed that SALL4 interacts with REN/KCTD11 (here REN), a substrate receptor subunit of the Cullin3-RING ubiquitin ligase complex (CRL3REN) and a tumor suppressor lost in ~30% of human SHH-MBs. We demonstrate that CRL3REN induces polyubiquitylation and degradation of wild type SALL4, but not of a SALL4 mutant lacking zinc finger cluster 1 domain (ΔZFC1). Interestingly, SALL4 binds GLI1 and cooperates with HDAC1 to potentiate GLI1 deacetylation and transcriptional activity. Notably, inhibition of SALL4 suppresses SHH-MB growth both in murine and patient-derived xenograft models. Our findings identify SALL4 as a CRL3REN substrate and a promising therapeutic target in SHH-dependent cancers.
AB - The Sonic Hedgehog (SHH) pathway is crucial regulator of embryonic development and stemness. Its alteration leads to medulloblastoma (MB), the most common malignant pediatric brain tumor. The SHH-MB subgroup is the best genetically characterized, however the molecular mechanisms responsible for its pathogenesis are not fully understood and therapeutic benefits are still limited. Here, we show that the pro-oncogenic stemness regulator Spalt-like transcriptional factor 4 (SALL4) is re-expressed in mouse SHH-MB models, and its high levels correlate with worse overall survival in SHH-MB patients. Proteomic analysis revealed that SALL4 interacts with REN/KCTD11 (here REN), a substrate receptor subunit of the Cullin3-RING ubiquitin ligase complex (CRL3REN) and a tumor suppressor lost in ~30% of human SHH-MBs. We demonstrate that CRL3REN induces polyubiquitylation and degradation of wild type SALL4, but not of a SALL4 mutant lacking zinc finger cluster 1 domain (ΔZFC1). Interestingly, SALL4 binds GLI1 and cooperates with HDAC1 to potentiate GLI1 deacetylation and transcriptional activity. Notably, inhibition of SALL4 suppresses SHH-MB growth both in murine and patient-derived xenograft models. Our findings identify SALL4 as a CRL3REN substrate and a promising therapeutic target in SHH-dependent cancers.
KW - medulloblastoma
KW - medulloblastoma
UR - https://publicatt.unicatt.it/handle/10807/328036
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85178929821&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85178929821&origin=inward
U2 - 10.1038/s41418-023-01246-6
DO - 10.1038/s41418-023-01246-6
M3 - Article
SN - 1350-9047
VL - 31
SP - 170
EP - 187
JO - Cell Death and Differentiation
JF - Cell Death and Differentiation
IS - 2
ER -